Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives.

ABSTRACT: Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solu

SUBMITTER: Buocikova V 

PROVIDER: S-EPMC7761669 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature